PLYX
Polaryx TherapeuticsยทNASDAQ
--
--(--)
--
--(--)
Is PLYX undervalued or overvalued?
- PLYX scores 0.00/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -51.36 P/E ratio, 79.58 P/B ratio, and 0.00% earnings growth, these metrics solidify its Neutral investment rating.
